Literature DB >> 17632132

Imperative indications for conservative management of upper tract transitional cell carcinoma.

Amy E Krambeck1, R Houston Thompson, Christine M Lohse, David E Patterson, Daniel S Elliott, Michael L Blute.   

Abstract

PURPOSE: We report our experience with patients with imperative indications for endoscopic treatment for upper tract transitional cell carcinoma.
MATERIALS AND METHODS: Between 1983 and 2004 we identified 37 patients with a solitary kidney, bilateral disease or preoperative creatinine greater than 2.0 mg/dl who underwent endoscopic treatment for localized upper tract transitional cell carcinoma. A retrospective chart review was performed.
RESULTS: Of the 37 patients 32 had a solitary kidney, 3 had bilateral disease and 2 had preoperative creatinine greater than 2.0 mg/dl. Median age at diagnosis was 75 years (range 56 to 88). Bladder cytology was positive or atypical in 15 of 31 patients (48%). Tumors were grade 1 to 3 in 2, 13 and 7 patients, respectively, and diagnosed visually in 15. At a median followup of 2.7 years for survivors 23 patients (62%) had a total of 56 upper tract transitional cell carcinoma recurrences. Grade and stage progression occurred in 3 and 3 patients, respectively. Ten of the 23 patients who experienced upper tract recurrence died of transitional cell carcinoma. Overall kidney preservation was achieved in 24 of the 32 patients (75%) with a solitary kidney. At last followup 24 patients had died, including 11 (29.7%) of transitional cell carcinoma, at a median of 2.9 years. Cancer specific survival at 5 years for this cohort was 49.3%.
CONCLUSIONS: Our results indicate that upper tract tumor recurrence occurs in a majority of patients with imperative indications for endoscopic treatment, underscoring the need for frequent surveillance. While most kidneys can be preserved, cancer specific death is common.

Entities:  

Mesh:

Year:  2007        PMID: 17632132     DOI: 10.1016/j.juro.2007.05.056

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma.

Authors:  Anil Kapoor; Christopher B Allard; Peter Black; Wassim Kassouf; Christopher Morash; Ricardo Rendon
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

2.  Percutaneous Management of Upper Tract Urothelial Carcinoma in a Transplant Kidney.

Authors:  Tolulope Bakare; Omer A Raheem; Rodney Davis; Samy Heshmat; Mohamed H Kamel
Journal:  Curr Urol       Date:  2015-11-10

Review 3.  Nephron-sparing Management of Upper Tract Urothelial Carcinoma.

Authors:  Francesca Suriano; Tommaso Brancato
Journal:  Rev Urol       Date:  2014

Review 4.  [Endosopic organ-sparing treatment of urothelial tumors of the upper urinary tract: indications and results].

Authors:  M Hruza; C Stock; D Teber; J J Rassweiler
Journal:  Urologe A       Date:  2008-07       Impact factor: 0.639

5.  Segmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter cancer.

Authors:  Shih Ya Hung; Wen Chou Yang; Hao Lun Luo; Chun-Chien Hsu; Yen Ta Chen; Yao Chi Chuang
Journal:  Int Urol Nephrol       Date:  2013-11-08       Impact factor: 2.370

6.  Conservative management of upper tract transitional cell carcinoma.

Authors:  Markian R Iwaszko; Amy E Krambeck
Journal:  Indian J Urol       Date:  2008-04

7.  Mitomycin C instillation following ureterorenoscopic laser ablation of upper urinary tract carcinoma.

Authors:  Omar M Aboumarzouk; Bhaskar Somani; Sarfraz Ahmad; Ghulam Nabi; Nicholas Townell; Slawomir G Kata
Journal:  Urol Ann       Date:  2013-07

8.  Holmium:YAG laser ablation of upper urinary tract transitional cell carcinoma with new Olympus digital flexible ureteroscope.

Authors:  Pablo Garrido Abad; Almudena Coloma Del Peso; Manuel Fernández Arjona
Journal:  Urol Ann       Date:  2013-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.